MET and brain neoplasm: In contrast to the previous studies which suggest that the dysregulation of HGF/c-Met pathway may affect TRAIL-sensitivity via upregulation of DR5 level [30], we found that both the levels of DR4 and DR5 protein were unaltered after knocking down c-Met in TRAIL-resistant brain tumor cells.